Skip to main content
. 2023 May 5;59:101981. doi: 10.1016/j.eclinm.2023.101981

Table 1.

Baseline characteristics of the participants.

Baseline characteristics Before matching
After 1:1 propensity-score matching
Azvudine (n = 245) Controls (n = 722) SMD Azvudine (n = 245) Matched controls (n = 245) SMD
Age (years), mean (SD) 69.13 (13.4) 66.89 (14.8) 0.159 69.13 (13.4) 69.25 (14.0) 0.022
Gender, n (%) 0.079 0.025
 Male 154 (62.9) 426 (59.0) 154 (62.9) 157 (64.1)
 Female 91 (37.1) 296 (41.0) 91 (37.1) 88 (35.9)
COVID-19 vaccination status 0.010 0.016
 Vaccinated 118 (48.2) 344 (47.6) 118 (48.2) 120 (49.0)
 Unknown 127 (51.8) 378 (52.4) 127 (51.8) 125 (51.0)
Time from symptom onset to treatment exposure, n (%) 0.334 0.012
 >5 days 214 (87.3) 537 (74.4) 214 (87.3) 215 (87.8)
 0–5 days 31 (12.7) 185 (25.6) 31 (12.7) 30 (12.2)
Severity at admission, n (%) 0.189 0.060
 Non-severe 88 (35.9) 196 (27.1) 88 (35.9) 81 (33.1)
 Severe 157 (64.1) 526 (72.9) 157 (64.1) 164 (66.9)
Concomitant treatments initiated at admission, n (%)
 Systemic steroid 64 (26.1) 152 (21.1) 0.119 64 (26.1) 56 (22.9) 0.076
 Antibiotics 130 (53.1) 265 (36.7) 0.333 130 (53.1) 138 (56.3) 0.065
 Immunomodulators 25 (10.2) 57 (7.9) 0.080 25 (10.2) 22 (9.0) 0.042

SMD, Standard mean difference.